Medicine · Français

Will NCT05852938 (Novartis Pharmaceuticals) still show a study completion date of 25 January 2028 or earlier when checked on 24 February 2028?

deadline 2028-02-24 confidence medium tier 1 evidence
71%Asturna estimate

Resolution criterion

Yes if, when NCT05852938 is read on clinicaltrials.gov on 24 February 2028, the exact API field protocolSection.statusModule.completionDateStruct.date — Study Completion Date is 25 January 2028 or earlier — that is, the date announced today has not been pushed back. A later recorded date counts as no. If OverallStatus is Terminated, Withdrawn, Suspended, or Unknown status, that counts as no — an unmaintained or halted record is treated as a failure to hold the date, not as a technicality. The value returned by the ClinicalTrials.gov API on the deadline prevails; where the record gives a month without a day, the last day of that month is used. If that exact field is absent or empty on an otherwise existing record, that also counts as no – a missing date is not evidence the deadline will be met, it is treated the same as a halted record.

Verified starting state

As of 14 November 2026: NCT05852938 is registered as ACTIVE_NOT_RECRUITING, sponsored by Novartis Pharmaceuticals, with 383 participants. Started 2023-07; announced primary completion 2027-08-10, announced study completion 2028-01-25. Record last updated 2026-04-01. The date under test is 2028-01-25. Source: clinicaltrials.gov/study/NCT05852938

What pushes it up

What pushes it down

What would move this number most

Whether patient follow-up or database locking procedures experience operational delays in late 2027.

How this number is built

Deadline2028-02-24
Base rate65%
Best evidencetier 1 · 2 article(s) used
Independent runs70 · 72 (spread 2 pts)
Confidencemedium
Evidence capnot triggered
Last revised2026-11-14 09:06
Modelgemini-3.5-flash

Sources consulted

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgANtier 4 · Yahoo Finance · 2026-07-16ClinicalTrials.gov record NCT05852938 (sponsor: Novartis Pharmaceuticals): overall status ACTIVE_NOT_RECRUITING; primary completion date 2027-08-10; study completion date 2028-01-25; status last verified by the sponsor 2026-03; record last updated 2026-04-01; enrollment 383 (actual)tier 1 · ClinicalTrials.gov (U.S. National Library of Medicine) · 2026-04-01